Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases有效性、安全性、耐受性及血清IgG谷浓度:10%透明质酸酶辅助皮下免疫球蛋白在美国原发性免疫缺陷病儿科患者中的应用JOURNAL OF CLINICAL IMMUNOLOGYIF5.72025-03-140OA
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label studyIMMUNOTHERAPY ADVANCESIF4.92024-03-010OAAI
Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naive patients with primary immunodeficiency diseasesINTERNATIONAL IMMUNOPHARMACOLOGYIF4.72021-11-017OAAI
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune GlobulinJOURNAL OF CLINICAL IMMUNOLOGYIF5.72021-05-262OAAI
Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseasesINTERNATIONAL IMMUNOPHARMACOLOGYIF4.72019-06-0111OAAI
Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency DiseasesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22019-02-010OAAI
Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22018-02-010OAAI
Infusion Parameters and Adverse Events in Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune GlobulinJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22018-02-010OAAI
Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22018-02-010OAAI
Response to the Letter to the Editor Regarding Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical TrialsJOURNAL OF CLINICAL IMMUNOLOGYIF5.72017-09-050OAAI
Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010OAAI
Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010OAAI
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North AmericaJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010PREAI
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficienciesCLINICAL AND EXPERIMENTAL IMMUNOLOGYIF3.82016-10-1847OAAI
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaJOURNAL OF CLINICAL IMMUNOLOGYIF5.72016-08-3151OAAI
Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over TimeJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-010OAAI
Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North AmericaJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-010OAAI
Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 StudiesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-011OAAI
Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22015-02-012PREAI
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency重组人透明质酸酶促进皮下输注人免疫球蛋白治疗原发性免疫缺陷JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22012-10-01111OA